Loading data for CTOR — first visit, this takes a few seconds.

Citius Oncology, Inc. (CTOR)

NasdaqCM: CTOR · 实时价格 · USD

0.86

+0.07 (8.86%)

收盘价： Sep 09, 2026, 7:25 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

暂无数据

买价	0.6
市值	97.3M
营收（TTM）	7.11M
净利润（TTM）	-46.1M
	3.53
	-0.48
	n/a
	n/a
市净率（TTM）	2.41
市销率（TTM）	13.70
财报日期	n/a

卖价	1.02
成交量	54,789
20日均量	81,104
开盘价	0.77
前收盘价	0.79
日内区间	0.75 - 0.87
52周区间	0.49 - 2.25
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 CTOR

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

板块 Healthcare

上市日期 Dec 8, 2022

员工人数 n/a

交易所 NasdaqCM

股票代码 CTOR

官网 https://citiusonc.com/overview/default.aspx

公司完整简介

财务表现

2025年，Citius Oncology的营收为0，较上一年的0增长undefined%。净利润为-24.76M，增长17.08%。

财务报表

财报意外

Citius Oncology 已于 Aug 14, 2026 发布季度财报：

营收为 $1.49M 低于预期 $0, ， Infinity% 同比增长.
每股收益为 -0.08 低于预期 -0.01, ， 0.00% 同比增长.

股价变动原因

新闻

3周前 · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

3月前 · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

4月前 · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4月前 · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

6月前 · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

第 1 页，共 2 页

Citius Oncology, Inc. (CTOR)